"I was immediately impressed by the level of knowledge and expertise of the Wellington Partners team. Their excellent knowledge and network in the tuberculosis and diagnostics markets, combined with the experience of their team, allowed them to quickly develop real insight and understanding of our business that will bring lasting benefit to the company."
Peter Wrighton-Smith
CEO, Oxford Immunotec
Wellington contact:
Rainer Strohmenger
| Harnessing the power of T cell measurement |
Oxford Immunotec is a fully integrated diagnostics company focusing on the measurement of cellular immunity. Its proprietary T-SPOT® platform allows for the quantitative detection of specific T cell responses in chronic infections and other diseases. T-SPOT.TB, Oxford Immunotec's lead product for the diagnosis of latent tuberculosis infection, is already marketed directly and via distributors in Europe, Canada and more than 40 other countries worldwide. The product addresses a significant medical need as one third of the world's population is infected with tuberculosis, a disease that causes two million deaths each year. Oxford Immunotec was founded in 2002 and is headquartered near Oxford, UK.
First investment: October 2007
Oxford Immunotec Limited
94C Milton Park
Abingdon, Oxon
OX14 4RY
United Kingdom
